AstraZeneca Spies Success For Antibody To Prevent COVID-19 Infection In Vulnerable

Could Be First With Pre-Exposure Authorization

 
• By Andrew McConaghie

While it is likely to be fourth to market, AstraZeneca’s long-acting antibody combination could help the US battle SARS-CoV-2 in vaccine-skeptical states, data from study suggests.

AstraZeneca
AstraZeneca's antibody combination, if authorized, will be fourth to market, but could prevent infection in vulnerable populations in whom vaccines are not fully effective, or in the unvaccinated.

More from Business

More from Scrip